YU57803A - Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja - Google Patents

Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja

Info

Publication number
YU57803A
YU57803A YU57803A YUP57803A YU57803A YU 57803 A YU57803 A YU 57803A YU 57803 A YU57803 A YU 57803A YU P57803 A YUP57803 A YU P57803A YU 57803 A YU57803 A YU 57803A
Authority
YU
Yugoslavia
Prior art keywords
heart disease
prevention
treatment
inhibitors
inhibitor
Prior art date
Application number
YU57803A
Other languages
English (en)
Inventor
Charles Dinarello
Benjamin Pomerantz
Leonid Reznikov
Alden Harken
Yolande Chvatchko
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of YU57803A publication Critical patent/YU57803A/sh
Publication of RS51125B publication Critical patent/RS51125B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi na korišćenje inhibitora IL-18 za pripremu leka za lečenje i/ili prevenciju srčanih bolesti, pre svega ishemične srčane bolesti. Kombinacija IL-18 inhibitora i/ili TNF antagoniste takođe se uključuju u lečenje i/ili prevenciju srčanih bolesti.[The invention relates to the use of an inhibitor of IL-18 in the preparation of a medicament for treatment and/or prevention of a heart disease, in particular ischemic heart disease. Combinations of an IL-18 inhibitor and/or a TNF antagonist are also considered for the treatment and/or prevention of a heart disease.
YUP-578/03A 2001-01-29 2002-01-28 Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja RS51125B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01101959 2001-01-29

Publications (2)

Publication Number Publication Date
YU57803A true YU57803A (sh) 2006-05-25
RS51125B RS51125B (sr) 2010-10-31

Family

ID=8176323

Country Status (32)

Country Link
US (1) US20040234523A1 (sh)
EP (1) EP1355668B1 (sh)
JP (2) JP4860897B2 (sh)
KR (1) KR100857376B1 (sh)
CN (1) CN1326562C (sh)
AR (1) AR032422A1 (sh)
AT (1) ATE380558T1 (sh)
BG (1) BG66483B1 (sh)
BR (1) BR0206819A (sh)
CA (1) CA2435466C (sh)
CY (1) CY1107203T1 (sh)
CZ (1) CZ305653B6 (sh)
DE (1) DE60224004T2 (sh)
DK (1) DK1355668T3 (sh)
EA (2) EA010180B1 (sh)
EE (1) EE05534B1 (sh)
ES (1) ES2295332T3 (sh)
HK (1) HK1062810A1 (sh)
HR (1) HRP20030609A2 (sh)
HU (1) HU229164B1 (sh)
IL (2) IL157024A0 (sh)
ME (1) ME00549B (sh)
MX (1) MXPA03006776A (sh)
NO (1) NO331083B1 (sh)
PL (1) PL213568B1 (sh)
PT (1) PT1355668E (sh)
RS (1) RS51125B (sh)
SI (1) SI1355668T1 (sh)
SK (1) SK287620B6 (sh)
UA (1) UA80676C2 (sh)
WO (1) WO2002060479A1 (sh)
ZA (1) ZA200305439B (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257585A2 (en) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
AU1174402A (en) 2000-10-11 2002-04-22 Viron Therapeutics Inc Nucleic acid molecules and polypeptides for immune modulation
US7718368B2 (en) 2000-12-04 2010-05-18 Viron Therapeutics Inc. Immunomodulatory protein and useful embodiments thereof
ES2384241T3 (es) 2003-05-13 2012-07-02 Merck Serono Sa Variantes activas de la proteína que fija IL-18 y usos médicos de las mismas
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP4961559B2 (ja) * 2004-03-11 2012-06-27 友昭 星野 インターロイキン１８阻害剤を有効成分とする疾患の予防又は治療剤
PL1885753T3 (pl) 2005-06-03 2011-12-30 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
AU2008324814B2 (en) * 2007-11-05 2013-05-16 Solventum Intellectual Properties Company Identification of tissue for debridement
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2014317035B2 (en) * 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
CN107660150B (zh) * 2015-03-05 2023-10-24 Ab2生物股份有限公司 Il-18结合蛋白(il-18bp)和抗体在炎性疾病中
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
NZ322197A (en) * 1995-11-21 1999-02-25 Yamanouchi Pharma Co Ltd Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
WO1998010778A1 (en) * 1996-09-12 1998-03-19 Idun Pharmaceuticals, Inc. INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS
WO1998024804A2 (en) * 1996-12-06 1998-06-11 Vertex Pharmaceuticals Incorporated INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
ES2146192T1 (es) * 1997-03-18 2000-08-01 Basf Ag Metodo y composiciones para modular la sensibilidad a los corticosteroides.
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE19743687C1 (de) * 1997-10-06 1998-11-26 Henkel Kgaa Detergensgemische und deren Verwendung
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18
EP1022027A1 (en) * 1999-01-22 2000-07-26 Applied Research Systems ARS Holding N.V. Tumor necrosis factor antagonists and their use in endometriosis
ATE336480T1 (de) * 1999-03-16 2006-09-15 Cytovia Inc Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
BR0009610A (pt) * 1999-04-09 2002-02-13 Cytovia Inc Inibidores de caspase e uso dos mesmos
AU6078500A (en) * 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
EA007014B1 (ru) * 2000-05-05 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Применение il-18 в качестве диагностического маркера
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
BG108128A (bg) 2004-11-30
CZ305653B6 (cs) 2016-01-27
KR20030070143A (ko) 2003-08-27
SK287620B6 (sk) 2011-04-05
HUP0303306A3 (en) 2005-12-28
HRP20030609A2 (en) 2005-06-30
PL213568B1 (pl) 2013-03-29
MXPA03006776A (es) 2003-10-24
CN1326562C (zh) 2007-07-18
DK1355668T3 (da) 2008-05-05
HU229164B1 (en) 2013-09-30
EE05534B1 (et) 2012-04-16
RS51125B (sr) 2010-10-31
CZ20032335A3 (en) 2004-07-14
IL157024A0 (en) 2004-02-08
JP2009102354A (ja) 2009-05-14
EE200300328A (et) 2003-10-15
EA200300844A1 (ru) 2003-12-25
JP2004522748A (ja) 2004-07-29
PL366802A1 (en) 2005-02-07
EP1355668A1 (en) 2003-10-29
NO331083B1 (no) 2011-10-03
EP1355668B1 (en) 2007-12-12
BG66483B1 (bg) 2015-03-31
ME00549B (me) 2011-10-10
AR032422A1 (es) 2003-11-05
SK10892003A3 (sk) 2004-02-03
CA2435466A1 (en) 2002-08-08
SI1355668T1 (sl) 2008-06-30
JP4860897B2 (ja) 2012-01-25
PT1355668E (pt) 2008-01-04
CY1107203T1 (el) 2012-11-21
IL157024A (en) 2014-02-27
ATE380558T1 (de) 2007-12-15
US20040234523A1 (en) 2004-11-25
EA200501549A1 (ru) 2006-04-28
HUP0303306A2 (hu) 2004-01-28
ES2295332T3 (es) 2008-04-16
EA006767B1 (ru) 2006-04-28
WO2002060479A1 (en) 2002-08-08
HK1062810A1 (en) 2004-11-26
KR100857376B1 (ko) 2008-09-05
DE60224004D1 (de) 2008-01-24
EA010180B1 (ru) 2008-06-30
CA2435466C (en) 2012-04-03
BR0206819A (pt) 2004-02-03
NO20033228L (no) 2003-09-26
CN1499982A (zh) 2004-05-26
ZA200305439B (en) 2004-07-15
NO20033228D0 (no) 2003-07-16
UA80676C2 (en) 2007-10-25
DE60224004T2 (de) 2009-07-23

Similar Documents

Publication Publication Date Title
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
WO2004006858A3 (en) Compounds, compositions, and methods employing same
SI1487541T1 (sl) Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
RS89204A (en) Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
MXPA03010761A (es) Combinaciones farmaceuticas.
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
GB0002336D0 (en) Medicaments
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
MY137620A (en) Therapeutic treatment
TW200507829A (en) New combination
GR1004358B (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
MXPA05005893A (es) Composicion farmaceutica de 1-(3-hidroxi -4-metoxifenil) -4-metil-5 -etil-7, 8-dimetoxi- 5h-2, 3-benzodiazepina y usos de la misma.
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
YU11904A (sh) Upotreba inhibitora il-18 kod poremećaja preosetljivosti
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks
TR200502061T2 (tr) IL-18 inhibitörlerinin kullanımı.
WO2001056590A3 (de) Verwendung von proteinkinase-inhibitor-alpha
WO2005000238A3 (en) Use of selective cyclooxygenase-2 inhibitors for the treatment of endometriosis
AP1731A (en) Use of an inhibitor of the renin-angiotensin system for the manufacture of a medicament or prevention of lipodystrophy syndorme.
WO2004002486A3 (en) Ciprofloxacin hci